BD1 gets Australian patent for cancer-related tech
BARD1 Life Sciences (ASX:BD1), a company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer, has gained patent approval from IP Australia for its “BARD1 isoforms in lung and colorectal cancer and use thereof”.
Chief Executive, Dr Learnne Hinch highlighted that this core patent family now has four granted patents in the US, Japan and China, as well as Australia.
This patent family protects the sequence of various BARD1 isoforms specific to lung and colorectal cancer, a method for detecting the presence of the specific BARD1 isoforms, and a method for treating and/or preventing lung cancer and colorectal cancer.
BD1’s patent portfolio as highlighted below includes five patent families covering various BARD1 DNA and protein sequences, methods of diagnosis and treatment, and use in multiple cancers.
The group’s lung cancer test is currently in development for the early detection of lung cancer, the fifth most common cancer and the leading cause of cancer deaths in Australia.
It should be noted, however, that this is an early stage biotech company and success is no guarantee. Investors should seek professional financial advice before making an investment.
The Australian Institute of Health and Welfare (AIHW) estimates that there will be 12,434 new cases of lung cancer diagnosed and 9,021 deaths from lung cancer in Australia in 2017. The latter represents 18.9% of all projected cancer deaths.
Hinch highlighted the fact that lung cancer is often diagnosed at a later stage after it has spread to other parts of the body, resulting in a 16% chance of survival after five years in Australia.
Early detection of lung cancer has the potential to save lives by enabling early treatment when it is potentially curable, but there is currently no approved blood test available for early detection of lung cancer in people without symptoms.
BD1’s technology uses novel tumour markers and a proprietary algorithm. The company also has a pipeline of technologies with similar goals such as the Ovarian Cancer Test which is aimed at the early detection of ovarian cancer, and the company also has high-value diagnostic and therapeutic projects at research stages for multiple cancers.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.